BX vs CME Stock Comparison
CME currently leads BX in this stock comparison, with AIQ scores of 57 vs 51. The clearest difference is momentum.
What is the main difference between BX and CME?
CME leads the current stock comparison as CME Group Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Blackstone Inc. vs CME Group Inc.
CME leads
CME leads by 6 AIQ points, primarily on Momentum and Risk Resilience, but the lead has narrowed from 12 points over 30 sessions. Wall Street currently favors BX on target upside.
Fragile: 4 of 6 evidence groups support CME, its lead is narrowing, and its current signal state is conflicted.
Blackstone Inc.
CME Group Inc.
The Algovestiq AIQ Score currently favors CME over BX, 57 versus 51 as of Oct 31, 2026. CME's advantage is driven primarily by stronger momentum and risk resilience. CME also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors BX. 4 of 6 covered evidence groups favor CME today, and the comparison is rated Fragile on stability: the leader's advantage has been narrowing. CME lead: Weakening — the AIQ differential moved from 12 to 6 points over 30 sessions.
Compare Blackstone Inc. and CME Group Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BX and CME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum53 vs 78CME +25
- Risk Resilience42 vs 53CME +11
- Value28 vs 25Even
- Quality76 vs 74Even
4 of 6 evidence groups favor CME. CME’s edge is concentrated in momentum and risk resilience.
What changed since the last close
Latest scored session 2026-10-30, compared against the prior scored session 2026-10-29.
No factor moved materially.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
No factor moved materially.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
CME's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — BX and CME both carry a full feed there.
The central trade-off
CME (CME Group Inc.): the stronger current systematic profile, led by momentum and risk resilience.
BX (Blackstone Inc.): the counter-case, on analyst expectations — but at materially higher volatility, 42.2% against 27.6%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
CMECME on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
CMECME on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
CMECME on the Momentum factor, by 25 points.
Lower downside
CMECME on Risk Resilience, by 11 points.
Analyst upside
BXBX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors CME, analyst targets favor BX. That disagreement is the most useful thing on this page.
| Measure | BX | CME | Note |
|---|---|---|---|
| Implied upside to target | +16.1% | +3.8% | BX has more room |
| Target dispersion | +37.1% | +34% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 11 | 8 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
Dividend growth
| Dividend metric | BX | CME |
|---|---|---|
| 5Y dividend CAGR | 24.71% | 8.02% |
| 2020 regular DPS | $1.370 | $3.400 |
| 2025 regular DPS | $4.132 | $5.000 |
| Years increased | 4 | 5 |
| No cut in window | No (1) | Yes |
| Cohort rank | not ranked | not ranked |
BX grew its split-adjusted regular dividend faster over 2020–2025 — 24.71% a year against CME's 8.02%. CME never reduced its regular dividend in the window; BX did in 1 year. They are ranked in different cohorts — variable-dividend payers and US dividend-paying corporations — so their ranks are not comparable with each other.
Yield and payout ratio shown elsewhere on this page are current values, not part of the study window.
Split-adjusted regular dividends per share, 2020–2025, excluding special dividends. Research as of Sep 19, 2026.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor CME. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | CME | 51 vs 57 |
| Fundamentals | CMEon balance | revenue growth -35.8% vs 1.8%; EPS growth -47.1% vs 1.4%; TTM ROE 40.8% vs 16.2%; gross margin 89.7% vs 84.3%; operating margin 52% vs 65.7% — CME takes 3 of 5 decided legs, not all of them |
| Valuation | Even | Value 28 vs 25 |
| Technicals | CME | Price vs 50-day -4.1% vs 8.6%; vs 200-day -6% vs 5% |
| Risk Resilience | CME | Risk Resilience 42 vs 53 |
| Analyst expectations | BX | Target upside 16.1% vs 3.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BX and CME and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 6 points.
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on CME.
How the comparison changed
120 daily snapshots · Jul 1 – Oct 30CME lead: Weakening — the AIQ differential moved from 12 to 6 points over 30 sessions.
- Today
- CME +6
- 51 vs 57
- 7 sessions ago
- CME +9
- 51 vs 60
- 30 sessions ago
- CME +12
- 44 vs 56
- 90 sessions ago
- CME +7
- 53 vs 60
The lead changed hands 5 times in this window, most recently on Aug 14 when CME moved ahead of BX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish, conflicted
Only BX
- Downtrend Structure Active — bearish, trend, long horizon
2 bullish / 1 bearish, conflicted
Only CME
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
Both carry 2 more signals that do not separate them: Death Cross Active, MACD Bullish Crossover.
CME leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.73%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +2.27%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BX closes the Momentum gap — currently 25 points behind, the largest single contributor to CME's edge.
- 2BX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3CME's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 6-point move would eliminate CME's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
CME leads on balance| Metric | BX | CME |
|---|---|---|
| Revenue growth (YoY) | -35.8% | 1.8% |
| EPS growth (YoY) | -47.1% | 1.4% |
| Gross margin | 89.7% | 84.3% |
| Operating margin | 52% | 65.7% |
| Return on equity (TTM) | 40.8% | 16.2% |
| Debt to equity | 1.61 | 0.13 |
Performance
CME leads 5 of 6 windows| Metric | BX | CME |
|---|---|---|
| 1 week (5 sessions) | 6.8% | -0.6% |
| 1 month (20 sessions) | 4.4% | 12.2% |
| 3 months (63 sessions) | -8.6% | 10% |
| 6 months (126 sessions) | -2.3% | 2.4% |
| Year to date | -24.1% | 7.7% |
| 1 year (252 sessions) | -24.3% | 9.1% |
Technicals
CME has the stronger structure| Metric | BX | CME |
|---|---|---|
| RSI (14) | 56.3 | 66.1 |
| ADX (14) | 31.7 | 30.6 |
| Price vs 50-day | -4.1% | 8.6% |
| Price vs 200-day | -6% | 5% |
| Volatility (1M, annualized) | 42.2% | 27.6% |
Risk
CME is the more resilient| Metric | BX | CME |
|---|---|---|
| Beta | 1.34 | -0.36 |
| Sharpe ratio | -0.62 | 0.37 |
| Sortino ratio | -0.94 | 0.51 |
| Max drawdown | -37.5% | -33% |
| Current drawdown | -28.4% | -9.9% |
| Annualized volatility | 37.3% | 25.1% |
| Value at risk (95%) | -4% | -2.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BX or CME?
On the Algovestiq AIQ Score, CME is the stronger of the two as of Oct 31, 2026, scoring 57 against BX's 51. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BX or CME the better buy right now?
CME carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the leader's advantage has been narrowing. Treat the lead as provisional.
Why does the AIQ Score favor CME over BX?
The composite weights Quality, Value, Momentum and Risk Resilience. CME leads Momentum by 25 points; CME leads Risk Resilience by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BX or CME?
Analyst price targets imply +16.1% upside for BX and +3.8% for CME, so the Street currently favors BX. That points the opposite way to the AIQ Score, which favors CME. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BX or CME?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BX or CME?
CME on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BX or CME?
CME on the Momentum factor, by 25 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BX or CME?
CME is the more resilient of the two, so the other name carries the higher downside risk. CME on Risk Resilience, by 11 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BX more profitable than CME?
The profitability evidence is mixed: gross margin 89.7% vs 84.3%; operating margin 52% vs 65.7%; ttm roe 40.8% vs 16.2%. BX leads on two measures and CME on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is CME's lead over BX getting stronger or weaker?
CME lead: Weakening — the AIQ differential moved from 12 to 6 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-07-01 and 2026-10-30. The lead has changed hands 5 times in that window, most recently on 2026-08-14, when CME moved ahead of BX.
What would change the BX vs CME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BX closes the Momentum gap — currently 25 points behind, the largest single contributor to CME's edge; BX's Death Cross Active resolves — a bearish trend rule currently active against it; CME's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 6-point move would eliminate CME's advantage entirely.
What do the current signals say about BX and CME?
BX: 1 bullish / 2 bearish, conflicted. CME: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BX is Death Cross Active (bearish, long horizon). On CME it is Death Cross Active (bearish, long horizon).
Compare BX and CME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.